Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Sponsor
Universita di Verona
Study ID
NCT06527534
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Filgotinib — DRUG
    Patients will receive pills of Filgotinib 200 mg qd for 12 weeks
  • Adalimumab — DRUG
    Patients will receive subcutaneous injections of Adalimumab 40 mg q2wk for 12 weeks

Study Details

Purpose: The study aims to investigate how Filgotinib affects proteins and micro-RNA in the blood of patients with rheumatoid arthritis. This could help understand its impact on inflammation and bone health in these patients. Study Design: This is a single-center, prospective randomized study.

Key Dates

Start date
Jul 15, 2024
Status verified
Jul 2024
Primary completion
Jul 15, 2025
Completion
Sep 15, 2025

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Filgotinib
    Filgotinib 200 mg qd
  • Active Comparator: Adalimumab
    Adalimumab 40 mg q2wk

Primary Outcome Measure

micro RNA (miRNA) [ Time Frame: 12 weeks ]

Central Contacts

Related Studies